IgGenix, Inc

#BacktoSchool season is here! For those managing food allergies for children headed back to school, preparation is key. Check out three essential steps to protect children against food allergies, and explore other strategies that parents, doctors, and schools should keep in mind: https://bit.ly/3StMJRi

Exciting!

IgGenix is thrilled to be initiating our first in-human clinical trial in Australia! The #ACCELERATEPeanut Study will evaluate the safety and tolerability of IGNX001 in peanut allergy. With this study, our team will be one step closer to transforming the way we treat #allergies and IgE-mediated diseases. As we kick off the trial this month, we extend our gratitude to the National Allergy Centre of Excellence for their support in making this study happen.

Groundbreaking work in #peanutallergy treatment is underway at IgGenix! We're proud to be featured in Channel 9 Australia for our work towards transforming allergy treatment through IgE antibodies to block the allergic cascade. This is a big step towards changing the face of allergic disease, and it's only the beginning. #TeamIgGenix

Today, we're recognizing #WorldCatDay and the companionship our feline friends provide! Cats are cherished members of many families, but cat allergies can often pose challenges, with symptoms ranging from mild to severe. At IgGenix, we're working to make a difference in the lives of those affected by allergies, including those sensitive to cat dander. Our research into IgE antibodies is helping pave the way for innovative solutions to tackle this common allergen. Learn more about our research focus areas: https://iggenix.com/

In honor of #WorldDogDay this Sunday, we're celebrating our four-legged friends and the joy they bring into our lives. For many, dogs are more than just pets - they are family. And just like our human family members, they too can suffer from #allergies and IgE-mediated diseases. At IgGenix, our commitment to transforming lives extends to our canine companions. We are actively working on innovative solutions to address allergies to dog dander, as well as the root cause of allergic reactions IN dogs. Just like humans, they can suffer from allergic reactions too. Learn more about our allergy research: https://iggenix.com/

IgGenix is proud to be hosting the investigator meeting for our first in-human #peanutallergy clinical trial in Australia! The ACCELERATE Peanut Study will evaluate the safety and tolerability of IGNX001 in peanut allergy. Thank you to the National Allergy Centre of Excellence for helping us bring this study to life. 

We're excited to share a feature from Allergic Living that spotlights our pioneering work at IgGenix: the development of a novel allergy therapy that aims to transform the way we treat allergic reactions by turning IgE (the antibody that triggers these reactions) into IgG4 antibodies to block the allergic cascade.   This innovative method has successfully moved from preclinical studies to human Phase 1 trials, and we’re proud of the dedication and progress we’ve made in our mission is to improve the lives of those living with #allergies and IgE-mediated diseases!   Read more about our groundbreaking efforts in the full article here: https://lnkd.in/gnVhEcUW

It is #WorldAllergyDay! Today and every day at IgGenix, we want to acknowledge the global community of individuals living with #allergies and IgE-mediated diseases. We understand the profound daily challenges these patients face and the significant impact these conditions can have on quality of life. As a dedicated team of scientists, clinicians, and advocates, we are steadfast in our commitment to transforming the lives of those affected by allergies and IgE-mediated diseases. Our mission is to provide innovative, effective treatments that address the root cause of these conditions. With the help of our SEQ SIFTER™ antibody discovery platform, we are developing therapies with the potential to prevent severe allergic reactions and IgE-mediated diseases. We're excited about the progress we have made thus far and are optimistic about the potential of our ongoing research, especially as we prepare to launch our first in-human clinical trial for #peanutallergy this month. Learn more about our work: https://iggenix.com/ #AllergyAwareness 

We're making headway on our "ACCELERATE PEANUT" study! Next month marks IgGenix's Investigator's Meeting, where we will be bringing together the investigators involved in our IGNX001 trial to discuss progress. This is an important step towards our goal to develop a therapy that can bring relief to patients suffering from #allergies by inhibiting the allergic cascade. Learn more about IgGenix's work: https://iggenix.com/ #clinicaltrials